PT - JOURNAL ARTICLE AU - Norikazu Matsunaga AU - Ayşe Ufuk AU - Bridget L. Morse AU - David W. Bedwell AU - Jingqi Bao AU - Michael A. Mohutsky AU - Kathleen M. Hillgren AU - Stephen D. Hall AU - J. Brian Houston AU - Aleksandra Galetin TI - Hepatic Organic Anion Transporting Polypeptide–Mediated Clearance in the Beagle Dog: Assessing In Vitro–In Vivo Relationships and Applying Cross-Species Empirical Scaling Factors to Improve Prediction of Human Clearance AID - 10.1124/dmd.118.084194 DP - 2019 Mar 01 TA - Drug Metabolism and Disposition PG - 215--226 VI - 47 IP - 3 4099 - http://dmd.aspetjournals.org/content/47/3/215.short 4100 - http://dmd.aspetjournals.org/content/47/3/215.full SO - Drug Metab Dispos2019 Mar 01; 47 AB - In the present study, the beagle dog was evaluated as a preclinical model to investigate organic anion transporting polypeptide (OATP)–mediated hepatic clearance. In vitro studies were performed with nine OATP substrates in three lots of plated male dog hepatocytes ± OATP inhibitor cocktail to determine total uptake clearance (CLuptake) and total and unbound cell-to-medium concentration ratio (Kpuu). In vivo intrinsic hepatic clearances (CLint,H) were determined following intravenous drug administration (0.1 mg/kg) in male beagle dogs. The in vitro parameters were compared with those previously reported in plated human, monkey, and rat hepatocytes; the ability of cross-species scaling factors to improve prediction of human in vivo clearance was assessed. CLuptake in dog hepatocytes ranged from 9.4 to 135 µl/min/106 cells for fexofenadine and telmisartan, respectively. Active process contributed >75% to CLuptake for 5/9 drugs. Rosuvastatin and valsartan showed Kpuu > 10, whereas cerivastatin, pitavastatin, repaglinide, and telmisartan had Kpuu < 5. The extent of hepatocellular binding in dog was consistent with other preclinical species and humans. The bias (2.73-fold) obtained from comparison of predicted versus in vivo dog CLint,H was applied as an average empirical scaling factor (ESFav) for in vitro–in vivo extrapolation of human CLint,H. The ESFav based on dog reduced underprediction of human CLint,H for the same data set (geometric mean fold error = 2.1), highlighting its utility as a preclinical model to investigate OATP-mediated uptake. The ESFav from all preclinical species resulted in comparable improvement of human clearance prediction, in contrast to drug-specific empirical scalars, rationalized by species differences in expression and/or relative contribution of particular transporters to drug hepatic uptake.